SCHEMBL15946347

SCHEMBL15946347

Cc1ccc2nc(-c3ccc4nc(-c5ccc(NC(=S)Nc6ccccc6)cc5)sc4c3)sc2c1S(=O)(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.57
SMN1; SMN2 Q16637 8/20 0.57
HPGD P15428 7/20 0.57
TP53 P04637 2/20 0.57
GAA P10253 2/20 0.57
GLA P06280 1/20 0.57
CYP3A4 P08684 1/20 0.57
NT5E P21589 1/20 0.57
CASP1 P29466 1/20 0.57
RECQL P46063 1/20 0.57
CASP7 P55210 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
MAPT P10636 11/20 0.53
NPC1 O15118 11/20 0.53
RAB9A P51151 10/20 0.53
KDM4E B2RXH2 7/20 0.53
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14768724 0.91 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL15946345 0.88 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL15939872 0.88 MMP2 (0.60) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL14768719 0.86 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL15946348 0.85 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL15946340 0.85 ALDH1A1 (0.68) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL14768678 0.85 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL14768667 0.83 SMN1; SMN2 (0.57) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL14768770 0.83 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HPGDTP53GAA
SCHEMBL14768609 0.83 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2HPGDTP53GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9464064-B2 HCV helicase inhibitors and methods of use thereof UNIVERSITY OF KANSAS (US) 2016-10-11 US disclosed
US-9464064-B2 HCV helicase inhibitors and methods of use thereof UNIVERSITY OF KANSAS (US) 2016-10-11 US disclosed
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof UWM RESEARCH FOUNDATION, INC. (US) 2014-08-14 US disclosed
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof UWM RESEARCH FOUNDATION, INC. (US) 2014-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140227225-A1 HCV Helicase Inhibitors and Methods of Use Thereof DHX15, DDX5, DHX35 ALDH1A1 1138/4885SMN1; SMN2 3980/4885HPGD 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.